PMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up 785% Year-Over-Year To $2.53 Million And Up 94% From Previous Quarter Files Form 10-Q For Q3 2026 Total Assets Of $133.1 Million Include $100.4 Million Held In Trust By Sponsored SPAC
| Quarterly revenue | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |||||||||||
| Revenue | $nil | $ | 285,948 | $ | 304,136 | $ | 681,994 | $ | 1,306,610 | $ | 2,530,364 | ||||||
| Sequential growth | n/a | n/a | 6% | 124% | 92% | 94% |
Balance Sheet Highlights as of September 30, 2026
- Total assets were approximately $133.1 million, compared to approximately $12.87 million at December 31, 2025 and approximately $14.94 million at September 30, 2025. The increase primarily reflects the consolidation of NSAI, including approximately $100.4 million of restricted cash held in NSAI's trust account (the“Trust Account”), together with the acquisitions of SVM and A&B Aerospace. Excluding restricted cash held in the Trust Account, total assets were approximately $32.7 million, up 154% from year-end 2025 and up 119% year-over-year. Cash, which excludes the Trust Account, was approximately $13.0 million, up 140% from approximately $5.4 million at December 31, 2025 and up 69% from approximately $7.7 million at September 30, 2025. Stockholders' equity attributable to PMGC was approximately $12.1 million, up 55% from approximately $7.84 million at December 31, 2025 and up 43% compared to September 30, 2025, after a non-cash charge of approximately $4.9 million to additional paid-in capital to remeasure NSAI's public shares to their redemption value.
Consolidation of NorthStrive Acquisition Corp I
PMGC, through its wholly owned subsidiary NorthStrive Sponsor I LLC, is the sponsor of NSAI, which completed its $100 million initial public offering on August 19, 2026. NSAI is consolidated in PMGC's financial statements beginning in the third quarter of 2026. The approximately $100.4 million in the Trust Account is held for the benefit of NSAI's public shareholders and is restricted cash that is not available to fund PMGC's operations, and an equal amount is presented outside of total equity as redeemable noncontrolling interest. Third quarter interest income of approximately $489,000 included approximately $423,000 earned on the Trust Account. The underwriters' over-allotment option in NSAI's initial public offering expired unexercised on October 1, 2026.
Operational Highlights
- Aerospace platform consolidated under A&B Aerospace. On July 2, 2026, AGA Precision Systems LLC merged into A&B Aerospace, consolidating PMGC's aerospace precision manufacturing under one company to share personnel, equipment, certifications and administrative support. A&B Aerospace, founded in 1948 and AS9100D certified, serves long-standing Tier 1 customers including Boeing, Honeywell and Moog, and contributed approximately $2.13 million of revenue at a 36.6% gross margin from its acquisition on May 11, 2026 through September 30, 2026. Long-term agreement with PAD Group. A&B Aerospace entered into a long-term agreement with Precision Aerospace & Defense Group, Inc. (“PAD Group”), effective July 23, 2026, to manufacture precision-machined aerospace and defense components under purchase orders, including orders associated with U.S. federal government prime contracts. The agreement has a two-year term with automatic one-year renewals and no guaranteed minimum purchase volume. Investment in automation and lights-out manufacturing. In August 2026, the Company announced that it has invested in advanced manufacturing equipment for its aerospace and defense manufacturing businesses, including a 5-axis machining center, a CNC lathe with Y-axis and live tooling and a Swiss-type CNC lathe with bar feeder that enables lights-out manufacturing, and that it is evaluating robotics and automation technologies to increase capacity and efficiency. Specialty IT packaging. Pacific Sun, which supplies protective packaging for semiconductor, data center and networking hardware to more than 300 commercial customers, generated a gross margin of 47.0% in the first nine months of 2026, up from 29.1% for the period from its acquisition in July 2025 through year-end 2025, which PMGC believes reflects improved unit economics under its ownership. Defense technology. NorthStrive Defense Tech LLC executed a definitive exclusive, worldwide license with the Florida State University Research Foundation for U.S. Patent No. 12,291,334, a multi-domain drone payload technology for aerospace and defense applications and engaged Deploy360 to independently validate the patented GPS-denied drone navigation technology it holds under option. Biosciences. NorthStrive Biosciences Inc. (“NorthStrive Biosciences”) reported positive results from Phase III of its AI-driven drug discovery program with Yuva Biosciences, in which four AI-selected candidates increased ANT1 protein expression in primary human skeletal muscle cells, and announced an expansion program to advance the four compounds toward lead and backup nomination for potential cardiac disease and obesity applications. It also announced two U.S. patent applications covering EL-22 and EL-32 for muscle loss in microgravity and a statement of work with Charles River Laboratories supporting both programs. Royalty stream. In September 2026, the Company announced a payment agreement with Longevity Health Holdings under which the acknowledged 2025 royalty of $94,937 and future royalties from a business the Company divested in January 2025 are payable to NorthStrive Biosciences in monthly installments of $10,000 beginning October 15, 2026.
Recent Developments Subsequent to Quarter-End
- Proposed NSAI business combination with Nuclea Energy. On October 30, 2026, NSAI entered into a definitive business combination agreement with Nuclea Energy Inc. (“Nuclea”), a development-stage company developing advanced nuclear technologies including the Morpheus Micro Modular Reactor, which was announced on November 2, 2026. The agreement provides for share consideration based on a $350 million value for Nuclea, subject to adjustments at closing, plus up to 15,000,000 earnout shares subject to the achievement of specified milestones. The proposed transaction is expected to close in the first half of 2027, and the agreement may be terminated if closing has not occurred by April 30, 2027. Closing is subject to conditions that include NSAI and Nuclea shareholder approvals, an effective registration statement on Form S-4, a receipt for a final Canadian prospectus, Nasdaq listing approval, completion of Nuclea's pending acquisition of the Moltex assets by November 30, 2026, and NSAI having available cash of at least $3.0 million at closing. PMGC, an existing investor in Nuclea, has agreed to subscribe for $1,845,000 principal amount of debentures issued by a Nuclea subsidiary to fund the Moltex acquisition. NSAI has disclosed substantial doubt about its ability to continue as a going concern if it does not complete a business combination by August 19, 2027. There can be no assurance that the proposed transaction will be completed. EL-32 preclinical results. On November 5, 2026, the Company announced the completion of NorthStrive Biosciences' preclinical proof-of-concept study of EL-32 in combination with semaglutide, which generated the first controlled in vivo data on EL-32 in a GLP-1 combination setting. The study identified a statistically significant greater absolute lean mass at the highest tested EL-32 dose in combination with semaglutide compared with semaglutide alone. The finding is preliminary and limited to specific measures and doses; the combination did not demonstrate a consistent additive metabolic benefit over semaglutide alone, and EL-32 alone did not demonstrate meaningful improvements. The contract research organization noted that the semaglutide dose used left a limited window to detect an additional effect of EL-32, and NorthStrive Biosciences plans to design a follow-on preclinical study using a lower dose of semaglutide, with lean mass and body composition as the primary endpoints. Investment in Orbit2Orbit. Following the non-binding term sheet announced in August 2026, PMGC Capital LLC completed a subscription for common shares of Orbit2Orbit Pty Ltd, an Australian space technology company developing in-space logistics and infrastructure, as announced on November 10, 2026.
In the first nine months of 2026, PMGC generated approximately $4.52 million of revenue, approximately 7.7 times its revenue for all of 2025, and quarterly revenue has grown from approximately $286,000 to approximately $2.53 million for the three-month periods ended September 30, 2025 and 2026, respectively. Since July 2025, the Company has completed five acquisitions and built an operating base with exposure to industries that PMGC believes are supported by strong, long-term demand: aerospace, defense and space; medical and semiconductor manufacturing; and the data center and AI infrastructure supply chain. Alongside that operating base, PMGC is advancing defense technology and biosciences development programs and has launched a SPAC sponsorship platform. The Company plans to continue investing in the capacity and automation of its existing businesses and to pursue additional acquisitions of established, cash-flow-positive businesses, and believes it is still early in building the scale of its platform.
Selected Financial Information (Unaudited, in U.S. Dollars)
Results of operations, three months ended
| September 30, 2026 | June 30, 2026 | September 30, 2025 | Change vs. Q2 2026 | Change vs. Q3 2025 | ||||
| Revenue | 2,530,364 | 1,306,610 | 285,948 | 94% | 785% | |||
| Gross profit | 601,444 | 385,691 | 78,030 | 56% | 671% | |||
| Gross margin | 23.8% | 29.5% | 27.3% | (5.7) pts | (3.5) pts | |||
| Total operating expenses | 3,080,365 | 4,212,900 | 2,276,931 | (27)% | 35% | |||
| Net loss from continuing operations | (2,220,853 | ) | (2,958,972 | ) | (2,616,018 | ) | Narrowed 25% | Narrowed 15% |
| Net loss | (2,242,738 | ) | (2,941,382 | ) | (2,594,320 | ) | Narrowed 24% | Narrowed 14% |
| Net loss attributable to PMGC stockholders | (2,406,301 | ) | (2,941,382 | ) | (2,594,320 | ) | Narrowed 18% | Narrowed 7% |
Selected balance sheet data
| September 30, 2026 | June 30, 2026 | December 31, 2025 | September 30, 2025 | ||
| Cash | 12,981,851 | 18,141,758 | 5,402,333 | 7,700,562 | |
| Restricted cash held in Trust Account | 100,422,693 | n/a | n/a | n/a | |
| Total assets | 133,101,280 | 36,564,496 | 12,868,473 | 14,938,018 | |
| Less: restricted cash held in Trust Account | (100,422,693 | ) | n/a | n/a | n/a |
| Total assets excluding restricted cash held in Trust Account (1) | 32,678,587 | 36,564,496 | 12,868,473 | 14,938,018 | |
| Total liabilities | 21,033,639 | 19,827,597 | 5,031,111 | 6,447,363 | |
| Redeemable noncontrolling interest | 100,422,693 | n/a | n/a | n/a | |
| Total PMGC Holdings Inc. stockholders' equity | 12,109,044 | 16,736,899 | 7,837,362 | 8,490,655 |
(1) Total assets excluding restricted cash held in the Trust Account is a non-GAAP financial measure. The Company presents it because the Trust Account is not available to fund PMGC's operations and its inclusion affects comparability with prior periods. The table above reconciles this measure to total assets, the most directly comparable measure under U.S. generally accepted accounting principles (“GAAP”). This measure should be considered in addition to, and not as a substitute for, total assets presented in accordance with GAAP.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit .
Additional Information and Where to Find It
In connection with the proposed business combination between NSAI and Nuclea, NSAI intends to file relevant materials with the SEC, including a registration statement on Form S-4, which will include a proxy statement/prospectus of NSAI. Investors and shareholders of NSAI are urged to read the registration statement and the proxy statement/prospectus, when they become available, and any other relevant documents filed with the SEC, because they will contain important information about the proposed transaction. The documents filed by NSAI with the SEC may be obtained free of charge on the SEC's website at. NSAI is a separate SEC registrant.
No Offer or Solicitation
This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities of PMGC or NSAI, or a proxy statement or the solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as“believes,”“expects,”“plans,”“potential,”“would” and“future” or similar expressions such as“look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC's filings with the United States Securities and Exchange Commission (“SEC”), including the“Risk Factors” section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact: ...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment